Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study

Albert A Hageè,1 Eric Caudron,2,3 Thibaud Damy,4 Raymond Roudaut,5 Alain Millaire,6 Caroline Etchecopar-Chevreuil,7 Thi-Chien Tran,3 Firas Jabbour,8 Catherine Boulcy,9 Patrice Prognon,2 Philippe Charron,9 Dominique P Germain3,10,11 on behalf of the FOCUS study investigators

ABSTRACT

Background Patients with Fabry disease (FD) show left ventricular hypertrophy (LVH) mimicking hypertrophic cardiomyopathy (HCM) of sarcomeric origin and might benefit, if detected early, from specific enzyme replacement therapy. The prevalence of FD in patients with LVH of 13 mm or greater, screened using the leucocyte alpha-galactosidase A (α-gal A) activity test, a technique that is difficult to apply routinely, ranged from 0% to 6%.

Objective To screen systematically for FD in patients with a diagnosis of HCM (LVH ≥15 mm) in primary cardiology practice, a validated, physician-friendly α-gal A assay was used on dried blood spots using a filter paper test.

Design and patients A cohort of 392 adults (278 men) followed for HCM were screened for FD. A standard blood test was used for confirmation in nine men in whom the α-gal A result was 40% or less.

Results Four men (1.5%; 1.8% of men) were diagnosed with FD. Index cases presented with diffuse but asymmetric LVH, with severe obstruction in one case and frequent high-grade atrioventricular conduction block necessitating a pacemaker in three cases. Family screening identified eight additional cases. Genotyping was performed successfully on DNA extracted from the filter paper.

Conclusion In male patients diagnosed as having HCM, pure FD cardiac variants are not exceptional and can be specifically identified using a simple filter-paper test. The sensitivity of this test is low in female patients.

Hypertrophic cardiomyopathies (HCM) are defined by the presence of increased left ventricular thickness or mass in the absence of loading conditions (hypertension, valve disease) sufficient to cause the observed abnormality. Several hundred mutations involving more than 10 different genes encoding sarcomeric proteins account for approximately 60% of HCM cases. While echocardiographic left ventricular hypertrophy (LVH) is the hallmark of the disease, there is a great heterogeneity of symptoms and prognoses among patients with sarcomeric HCM, some having a statistically normal life expectancy and others having a high risk of sudden death, congestive heart failure, or stroke due to atrial fibrillation.
patients were included if they met the following criteria: (1) age 18–79 years; (2) HCM defined as the presence of two-dimension-\al{sional echocardiographic LVH of unknown cause, such as severe hypertension or valvular aortic stenosis, with a maximum end-\al{diastolic wall thickness of 15 mm or greater in any segment;}{16} and (3) no genetic testing for HCM and no known FD or sarcocereic mutation in the patient and their family. Only patients with mild to moderate hypertension were included in the study as most data suggest that moderate to severe hyper-\al{tension (wall thickness $>2.1$ mm) is rare in white people with mild to moderate hypertension.}{18} Left ventricular wall thick-\al{nesses were measured directly at end-diastole on echographic two-dimensional parasagittal short-axis views (either at the base, papillary muscle or apex levels) using fundamental imaging and taking care to adjust the cut-planes perpendicular to the left-\al{ventricular long axis; the greatest thickness as measured at any site within the left ventricular wall using the leading edge method represented the maximum wall thickness.}{21} 6

**Data collection and diagnostic tests**

Patients’ demographic characteristics, HCM-related medical history, echocardiographic measurements and current drug therapy were recorded at inclusion. Blood was drawn from every patient by venipuncture. Five drops from each blood sample were directly spotted on two filter papers. The spots were dried at room temperature for 8–72 h and then stored at $+2^\circ$ to $+6^\circ$C for up to 2 months before being centrally processed (Laboratoire de génétique médicale, Garches, France); $\alpha$-gal A activity was then measured from dried blood spots (DBS) on filter paper using a fluorimetric method with modifications as described previously. When $\alpha$-gal A activity was greater than 40% compared with the control, a threshold determined from the results obtained from a different genotyped cohort (see below), the test was considered negative and there was no follow-up visit. The rela-\al{tively high activity threshold was chosen in an attempt to detect FD disease in women, because a high enzymatic activity in women cannot accurately exclude heterozygosity for FD.}{20} When activity was 40% or less, a second visit was scheduled to answer a questionnaire oriented to characterise signs or symp-\al{toms of FD (family history, acute or chronic peripheral neuropathic pain in adolescence, decreased ability to sweat, cornea verticillata, angiokeratoma, gastrointestinal complaints, renal dysfunction, proteinuria, or stroke at age <55 years), and confirm FD diagnosis using a leucocyte enzyme activity measure test in men and genotyping in women. To do so, blood samples were shipped to the central laboratory within 96 h. Enzyme activity was assessed by a fluorimetric method on leucocytes and genotyping was performed on DNA extracted from the filter papers.}{21}

**Accuracy of the DBS screening test**

Filter paper test accuracy has been validated previously, being compared with the leucocyte enzyme activity measure test. Furthermore, we tested the accuracy of the DBS test on an independent cohort of 209 subjects (128 genotyped FD patients - 60 men, 68 women - and 81 healthy controls). The enzymatic activity of $\beta$-galactosidase on DBS was found to be normal for all patients, suggesting the absence of any pre-analytical problem. A positive screening test was defined by an $\alpha$-gal A activity of less than 2.1 $\mu$mol/h per litre, which represented 40% of the median activity of controls (5.3 $\mu$mol/h per litre; mean±SD (range) 5.6±2 (2.6–10.7) $\mu$mol/h per litre), allowing us to eliminate false-positive results. In hemizygous men, $\alpha$-gal A activities were all less than 1.1 (0.11±0.2) $\mu$mol/h per litre. In heterozygous women, $\alpha$-gal A activity was 2.2±1.7 $\mu$mol/h per litre, ranging from 0 to 7.8 $\mu$mol/h per litre. Using this threshold ($\alpha$-gal A <40% of controls), the specificity of the test was 100%, whereas the sensitivity was 82% (100% in men but only 66% in women).

**PCR conditions**

The PCR were performed as follows: final volume sample 50 $\mu$l; 2 mm of dried blood from the filter paper as a source of DNA, 25 $\mu$l water, 2.5 pmol of each primer, and 20 $\mu$l of Phusion Blood direct PCR (Finnzymes Inc, Massachusetts, USA) were used. An initial denaturation at 95°C for 5 min was followed by 55 cycles of 50 s at 95°C, 30 s at 58°C, 1 min at 72°C, and a final 10 min at 72°C.

**Genotyping**

Direct sequencing was performed by Beckman Coulter Genomics (Essex, UK). PCR products were purified by Agen-\al{court AMPure XP (Beckman Coulter Genomics). A 5730xl Analysyer (Applied Biosystems Inc, California, USA) was used to obtain DNA sequences, which were subsequently handled with Navigator 2.0 software.}{21}

**Data analysis**

At least 569 patients had to be included in the study to allow an accurate estimation of the prevalence of FD, with an expected value of 4% and a 95% CI from 2% to 6%. When appropriate, results are expressed as mean±standard deviation (SD) (range). Groups have been compared using a non-parametric Wilcoxon test for continuous variables and Fisher’s exact test for categorical variables.

**RESULTS**

**Study population**

Three-hundred and ninety-two patients (278 men) were included in the study (table 1).

A diagnosis of HCM was established at least 5 years earlier in more than 50% of patients and was new in 124 cases (51.6%). Fifty-one patients older than 65 years were hypertensive (61.5%) and all of them had been followed for HCM for more than 5 years. A family history of HCM or sudden death was observed in 22% and 14% of men, respectively, and in 41% and 27% of women. The inheritance pattern a priori excluded the X-linked FD (father–son transmission) in 28 cases. Syncope or presyn-\al{copne, angina, heart failure and atrial arrhythmias (permanent, sustained, or not) were the most common symptoms. Previous ventricular arrhythmias were not infrequent, with 34 patients having experienced ventricular tachycardia, five having experience-\al{nd sudden death due to ventricular fibrillation (all implanted with an automatic internal cardiac defibrillator), and four patients with ventricular premature beats of Lown class 3. Malignant LVH (≥50 mm) was observed in 6% of men and 3% of women (p=0.12). During the study, two women died of cardiac causes (one after cardiac transplantation and one of sudden death), three men were resuscitated after sudden death (one with an appropriate shock from his defibrillator), and six patients were hospitalised for worsening heart failure. No endomyocardial biopsy was performed in that cohort.}{21}

**Screening results**

Among women, all had suitable filter paper tests and enzyme activity greater than 40% and no FD was diagnosed. Among men, three had non-useful filter paper tests, as a result of

132

Heart 2011;97:131–136. doi:10.1136/hrt.2010.200188
confirmed conservation problems, and nine had filter paper residual enzyme activities below the defined cut-off of 40%—markedly decreased (<17%) in four cases and slightly below the cut-off value (range 35–59%) in five cases—leading to a second enzymatic assay performed on leucocytes. Among those nine patients, the five with enzyme activities between 55% and 39% on filter papers (i.e. slightly below the initially defined cut-off value for the leucocyte assay) were found to have a leucocyte enzyme activity greater than 40%, while DNA sequencing failed to identify a pathogenic mutation in the GLA gene. In contrast, the remaining four patients with markedly reduced enzyme activity on DBS (<17%) were all confirmed as having FD, with a leucocyte enzyme activity between 5% and 17%. The prevalence of FD was thus 1.5% (95% CI 0.4 to 3.8) in our cohort of 275 men with interpretable filter paper tests and 1.8% in men above 40 years of age.

**GLA gene mutations**

For patients 1 and 2, sequencing was performed on PCR products obtained after amplification of DNA extracted from leucocyte pellets. For patients 3 and 4, direct sequencing was performed on purified PCR products obtained from direct amplification of DNA eluted from a 3 mm punch of DBS from filter paper in the PCR mix. Patient 1 was shown to carry a G to C transversion at position c. 486 in exon 3 of the complementary DNA sequence, leading to a missense mutation (p.Trp162Cys). Patients 2 and 3 were both shown to carry a T to C transition at position c. 537 in exon 2 the cDNA sequence of the GLA gene, also leading to a missense mutation (p.Phe113Leu). Interestingly, these two patients—who do not know each other—are both of Portuguese ancestry. Haplotype studies are ongoing to determine whether they are related or not. Patient 4 was shown to carry an A to G transition at position c. 644 in exon 5 of the cDNA sequence (missense mutation p.Asn215Ser). In all cases, sequencing of the rest of the GLA gene revealed no other abnormality.

**Characteristics of FD patients**

The mean age of the four men with FD was not significantly different from that of the remaining male patients of the cohort (52±8 years (42–59) vs 55±15 years (18–79), respectively, p=0.88). While all patients showed diffuse but asymmetric LVH, a septal to posterior wall ratio greater than 1.5 was not observed. Two patients presented with systolic anterior motion of the mitral valve and outflow tract obstruction, severe in one case, leading to septal ablation (table 2).

Left ventricular ejection fraction was normal in all cases. No FD patients presented with right ventricular hypertrophy or aortic root dilatation; FD patients with systolic anterior motion of the mitral valve showed mild mitral regurgitation, and one FD patient presented with minimal aortic regurgitation. Three patients (1, 2 and 4) underwent permanent pacemaker implantation due to symptomatic high-grade atrioventricular block at 43, 47 and 55 years of age, compared with only one patient in the remaining cohort. No patient reported characteristic signs or symptoms of FD. Moreover, there was no medical history of pain, angiookeratoma, cornea verticillata or proteinuria. On a systematic brain magnetic resonance imaging scan, one patient had a small lacunar infarction, whereas all the others tested normal. Another patient showed mild proteinuria, with an estimated glomerular filtration rate normal for his age. Pedigree analysis identified two half-brothers at risk of FD for patient number 4, and sequencing of the GLA gene confirmed the diagnosis of FD through the identification of a missense mutation in exon 5 of the gene (p.N215S). Interestingly, diffuse but asymmetric LVH of unknown cause existed for both of them. Furthermore, six heterozygous women were identified through pedigree analysis in three families.

**DISCUSSION**

In FD, α-gal A deficiency causes progressive accumulation of globotriaosylceramide and related glycosphingolipids in heart.
Cardiomyopathy
tissues, such as cardiomyocytes, conduction system cells, valvular fibrocytes and both vascular endothelial and smooth muscle cells. This heart tissue accumulation potentially leads to irreversible cardiac damage. Cardiac FD manifestations include LVH, arrhythmias, conduction defects and, more rarely, coronary artery disease (mainly due to small-vessel disease). It contributes to a reduced life expectancy of affected patients due to malignant arrhythmias and heart failure. Whereas, in parallel with multisisceral involvement, nearly all FD patients will develop LVH, the extent of which both increases with age and is accompanied by a progressive reduction in left ventricular function. LVH may also be the predominant feature of the disease in some patients presenting as cardiac variants, even if the existence of pure cardiac variants remains controversial.23 Previous systematic screening of FD has been performed using α-galactosidase A enzyme activity measured in leucocytes with the fluorogenic substrate 4-methylumbelliferyl-α-D-glucopyranoside, currently the gold standard for diagnosing FD in male patients.17 More recently, α-galactosidase A enzyme activity dosage on DBS using a filter paper test has been proposed as an alternative diagnostic test,17 and has been found to be as accurate as assays using leucocyte samples.18,19,22 The accuracy of this test is also demonstrated by results currently reported in a separate genotyped cohort (see Patients and methods section), with both sensitivity and specificity reaching 100% in men, whereas in women, as expected, sensitivity was lower (66%). However, the diagnosis of FD in women can occasionally be made using this method in the cases in which a markedly decreased residual enzyme activity is evidenced, and thus women were included in the current study.24 Moreover, those samples are easy to transport and are stable at room temperature for at least 20 days, making them suitable for screening patients at risk of FD. Leucocyte α-galactosidase A enzyme activity assays can be used to confirm positive filter paper test results and verify negative results in patients with a clinical suspicion of FD.

The novel aspect of this study is the use of blood spot analysis from physician-friendly filter papers as a practical way of conducting the screening. This was the source of the enzyme assay and could also be used as a source of DNA. Moreover, the prevalence of FD in individuals diagnosed with HCM was based on the consensus LVH diagnosis threshold (15 mm) in a large number of primary cardiology centres. The prevalence of FD is more frequent in male patients with late onset (≥40 years) HCM; accordingly, in the current study, no men less than 40 years of age were diagnosed with FD, compared with 1.8% of those aged over 40 years. It also demonstrates the accuracy of screening with the filter paper test, confirmed by both the gold standard enzymatic assay on white blood cells and genotyping (specificity 100% if a 50% threshold for residual α-galactosidase A activity is used). The filter paper test failed to detect any female patient with FD, but heterozygotes may have been missed as no systematic sequencing was carried out and as the test has a low sensitivity in women. From a practical point of view, the risk that a woman with clinically significant FD may not be diagnosed by a screening test based primarily on α-galactosidase A enzyme activity measurement remains high,14 and justifies efforts to collect clinical signs or medical history that should encourage first-line genotyping. In a recent cohort using systematic genetic screening in 90 HCM probands, 59 without sarcomere gene mutations, α-galactosidase A mutations were found in three of 90 (3%) HCM families and in two of 20 (10%) women without sarcomere gene mutations; none of the probands presented other indices of FD.25 This finding supports systematic testing for FD and underlines the fact that enzyme measurements are sufficient in men, but genetic testing is needed in women. Finally, genotyping was performed for the first time on PCR products obtained from DNA eluted directly from filter paper (figure 1). This may prove useful in the future for all cases for which obtaining a second sample may be difficult as well as for the genotyping of women for whom the enzymatic assay is not satisfactory and no efficient screening alternative is currently available.

Our results are in line with data from Montserrat et al13,15 in which a prevalence of FD of 1% has been estimated in a population of 508 men and women with HCM of presumed sarcomeric origin. Others cardiac variants have been identified in cohorts of patients with unexplained LVH of 13 mm or greater and systematically screened for FD, with an overall prevalence of approximately 3% in men (up to 6% in those aged above 40 years)17 and up to 12% in women (in a single study for which methodological bias cannot be excluded).14 Conversely, no patients with FD were found in highly selected groups with HCM, either in severely symptomatic obstructive patients who underwent surgical procedures to relieve the gradient,26 or in

Figure 1 Direct sequencing of polymerase chain reaction products obtained from amplification of DNA eluted directly from the 3 mm punch of dried blood spot from filter paper (patient 3). Patient 3 was shown to carry a T to C transition at position c. 337 in the cDNA sequence (arrow). This nucleotide substitution alters the codon (TTT) for phenylalanine to the codon (CTT) for leucine at position 113 of the α-galactosidase A protein (p. Phe113Leu). Despite scanning of the rest of the gene, no other sequence abnormality was found.
systematically genotyped patients.12 The apparent discrepancies between these different results may be related to the different methods used (type of population selected, assay methods).

While echographic asymmetric LVH has been described in patients with FD, diffuse, concentric and homogeneous LVH is the more frequently reported pattern.5 6 The current study demonstrates, quite unexpectedly when compared with a previous study,24 that cardiac variants may show asymmetric LVH and may go unrecognised for decades. However, a septal to posterior wall ratio greater than 1.5 was not observed. Severe obstruction leading to septal ablation is infrequent, but has been reported.27 Syncope associated with high-grade aorticventricular block seems to be a rather specific characteristic of the FD cardiac variant in this study, as three out of four patients diagnosed with FD presented with a syncopal high-grade aorticventricular blockage leading to permanent pacemaker implantation.

Conclusions In men diagnosed with HCM, cardiac variants of FD are not exceptional and might benefit from specific ERT. These patients may be screened systematically for FD with a simple fluorimetric method using DBS on filter paper test, which has become a very efficient first-line diagnostic test for screening in a general cardiology setting. High-degree aorticventricular block is frequent in that population. As the outcome of specific ERT is less efficient in advanced cases of FD, before extensive myocardial fibrosis is present,4 26 such a screening method using a simple test appears to be clinically relevant.

Acknowledgements The authors acknowledge the Centre d’Investigations Cliniques (Michel Azzi, MD, Anne Blanchard, MD), Hôpital Européen Georges Pompidou, Paris. The authors would like to thank Olivier Charbonnay for his assistance in collecting and interpreting the data, and they thank the centres (listed in alphabetical order) and investigators participating in the FOCUS study, and the ‘Groupe Cardiomyopathies et Insuffisance Cardiaque’ of the French Society of Cardiology: Besançon—Centre Hospitalier Universitaire Saint-Jacques (Yvette Bernard), Hôpital Jean Minjoz (Joanna Oettinger, Marie-France Seronde); Boulogne-Billancourt—Hôpital Ambroise-Pâris (Florence de Rozquefeuil, Olivier Dubourg, Laurent Gouya, Laurence Dall’Amonds); Brest—Hôpital de la Côte Blanche (Yannick Jobic), Cergy-Pontoise—Centre Hospitalier René Dubos (Patrick Jourdain); Dijon—Hôpital Militaire Percy (Eric Permer), Clermont-Ferrand—Centre Hospitalier Universitaire G Montpied (ëme Théodore Amonchot, Bernard Citron); Créteil—Hôpital Henri Mondor (Thibault Damy, Jean-Luc Dubois-Rande, Philippe Lecorvoisier); Dijon—Hôpital du Bocage (Jean-Christophe Eicher, Pierre Henry Gacon, Isabelle L’Hullier), La Martinière—Centre Hospitalier Le Mᵉ ynard (Elisabeth Sarrazin), La Réunion—Centre Hospitalier Sud Réunion (Christophe Jeannot, Catherine Mimran), Lille—Hôpital Cardiologique (Alain Milhare), Limoges—Centre Hospitalier Universitaire Régional Dupuytren (Caroline Etchecopar-Cherewul, Jérôme Lesage), Lyon—Hôpital Cardiologique Louis Pradel (Christophe Bouvagnet, Geneviève Delhommeau, Isabelle Lhuillier); Lyon—Centre Hospitalier Universitaire (Stéphane Cadet); Marseille—Centre Hospitalier Universitaire Laennec (Jean-Emmanuel Emsley), Montpellier—Hôpital Arnaud de Villeneuve (Dinh Thien-Tri Cung, Jean-Marc Davy, Catherine Sportouch-Dukan); Nantes—Centre Hospitalier Universitaire G et R Laennec (Jean-François Guelfi, Jean-Marc Langlard, To Ngoc Tram To, Jean-Noël Trochu), Nîmes—Centre Hospitalier Universitaire Caremeau (Stéphane Cadet); Paris—Hôpital Bichat (Marie-Aude Caut, Guillaume Jondeau); Paris—Centre Hospitalier Universitaire de Brabois (Yves Juliere). The following individuals provided expert technical help in the laboratory: Pierre Chamirand, Isabelle Delhom, Ramzi Ezarragi, Coralie Favier, Cindy Gallerne, Laetitia Lacastignatte, Maryline Le Boubin, Anne-Isabelle Martin-Mista, Gwen Page and Jean-François Perrault. This study was promoted by the French Society of Cardiology, with particular help from the Commission Promotion et Recherche Clinique [Dr Anissa Bouzamondo and Emile Nornotte].

Funding This study was supported by Genzyme SAS, Saint-Germain en Laye, France and the Centre de Référence de la maladie de Fabry et des maladies héréditaires du tissu conjonctif, CHU Raymond Poincaré, Garches, France.

Competing interests AAH and DPG have received research and consultancy funding from Genzyme SAS, Saint-Germain en Laye, France.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of the ethical committee of Pitie Salpêtrière, Paris, no 11-06, favourable advice 20 March 2006, France.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study

Albert A Hagège, Eric Caudron, Thibaud Damy, Raymond Roudaut, Alain Millaire, Caroline Etchecopar-Chevreuil, Thi-Chien Tran, Firas Jabbour, Catherine Boucly, Patrice Prognon, Philippe Charron and Dominique P Germain

Heart 2011 97: 131-136 originally published online November 9, 2010
doi: 10.1136/hrt.2010.200188

Updated information and services can be found at:
http://heart.bmj.com/content/97/2/131

These include:

References
This article cites 27 articles, 13 of which you can access for free at:
http://heart.bmj.com/content/97/2/131#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Editor's choice (227)
Drugs: cardiovascular system (8842)
Hypertrophic cardiomyopathy (314)
Epidemiology (3752)
Metabolic disorders (1030)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/